A new report finds that the U.S. government awarded several drug makers contracts for coronavirus research using agreements that would allow authorities to bypass laws that could ensure taxpayer-funded medicines or vaccines are affordable.
In recent months, the Department of Defense and the Biomedical Advanced Research and Development Authority signed or extended contracts with four companies — the Janssen unit at Johnson & Johnson (JNJ), the Genentech unit at Roche (RHHBY), Regeneron Pharmaceuticals (REGN), and Ology Bioservices — for research on either Covid-19 vaccines or medicines.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
